

USP Excipients Workshop: Impact of Lipids on the Design and Quality of Liposomal Drug Products (On-Demand)

| | |
|-----------------|-------------------|
| Art. ID | USP-EXC-WS-15 |
| Unit | Each |
| Deliverydetails | No Dangerous Good |

Description

"The liposomal "commercial"" lipid pool has little variation, and "fancy"" lipids (e.g., potentially useful for gene and DNA/RNA delivery, immunological targeting, fusogenic/cationic lipids) are mostly avoided. Shaping lipids into liposomes is becoming more of an engineering act than an art form. The first bioequivalent doxorubicin liposome has been approved. (Webcast 36 minutes)"